{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:26:31Z","timestamp":1787495191124,"version":"build-2736575974"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cisplatin-induced nephrotoxicity limits its anticancer effectiveness, thus this study\u2019s aim was to assess the potential modulatory effect of perindopril on cisplatin-induced nephrotoxicity and to elucidate the possible underlying mechanisms. Renal dysfunction was induced in mice by a single injection of cisplatin (10 mg kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    ,\n                    <jats:italic>i.p.<\/jats:italic>\n                    ) and perindopril was administered orally (2 mg kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    , once daily) for 5 days. Perindopril remarkably ameliorated cisplatin-induced perturbations in renal histology, renal levels of tumor necrosis factor-alpha, interleukin-6 and interleukin-10, apoptosis-regulating protein expressions (Bax and Bcl2), and partially normalized Bax to Bcl2 ratio and active caspase 3 protein expression. Conversely, perindopril had no significant effect on cisplatin-induced elevations in serum creatinine and urea, microalbuminuria, kidney to body weight ratio, lipid peroxidation marker, superoxide dismutase and catalase activities and reduced glutathione content. In conclusion, perindopril may be safely used with cisplatin in mice since it ameliorated cisplatin-induced histopathological changes, inflammation and apoptosis without affecting renal biomarkers or oxidative stress.\n                  <\/jats:p>","DOI":"10.2478\/acph-2020-0033","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:24:26Z","timestamp":1590492266000},"page":"515-525","source":"Crossref","is-referenced-by-count":12,"title":["Modulatory effects of perindopril on cisplatin-induced nephrotoxicity in mice: Implication of inflammatory cytokines and caspase-3 mediated apoptosis"],"prefix":"10.2478","volume":"70","author":[{"given":"Naif","family":"Aljuhani","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology , College of Pharmacy Taibah University , Al-Madinah Al-Munawwarah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed S.","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology , Faculty of Pharmacy Al-Azahr University , Cairo , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"El-Awady","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology , College of Pharmacy Taibah University , Al-Madinah Al-Munawwarah, Saudi Arabia"},{"name":"Department of Pharmacology and Toxicology , Faculty of Pharmacy Mansoura University , Mansoura , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Memy H.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology , College of Pharmacy Taibah University , Al-Madinah Al-Munawwarah, Saudi Arabia"},{"name":"Department of Pharmacology and Toxicology , Faculty of Pharmacy Al-Azahr University , Cairo , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"2026051108202589498_j_acph-2020-0033_ref_001_w2aab3b7b3b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. S. Dasari and P. B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action, Eur. J. Pharmacol.740 (2014) 364\u2013378; https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.02510.1016\/j.ejphar.2014.07.025","DOI":"10.1016\/j.ejphar.2014.07.025"},{"key":"2026051108202589498_j_acph-2020-0033_ref_002_w2aab3b7b3b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. I. Arany and R. L. Safirstein, Cisplatin nephrotoxicity, Semin. Nephrol.23 (2003) 460\u2013464; https:\/\/doi.org\/10.1016\/S0270-9295(03)00089-510.1016\/S0270-9295(03)00089-5","DOI":"10.1016\/S0270-9295(03)00089-5"},{"key":"2026051108202589498_j_acph-2020-0033_ref_003_w2aab3b7b3b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. A. Shiraishi, K. Sakumi and M. Sekiguchi, Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase, Carcinogenesis21 (2000) 1879\u20131883; https:\/\/doi.org\/10.1093\/carcin\/21.10.187910.1093\/carcin\/21.10.187911023546","DOI":"10.1093\/carcin\/21.10.1879"},{"key":"2026051108202589498_j_acph-2020-0033_ref_004_w2aab3b7b3b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. N. Pabla and Z. Dong, Cisplatin nephrotoxicity: mechanisms and renoprotective strategies, Kidney Int.73 (2008) 994\u20131007; https:\/\/doi.org\/10.1038\/sj.ki.500278610.1038\/sj.ki.500278618272962","DOI":"10.1038\/sj.ki.5002786"},{"key":"2026051108202589498_j_acph-2020-0033_ref_005_w2aab3b7b3b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. P. D. Sanchez-Gonzalez, F. J. Lopez-Hernandez, J. M. Lopez-Novoa and A. I. Morales, An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity, Crit. Rev. Toxicol.41 (2011) 803\u2013821; https:\/\/doi.org\/10.3109\/10408444.2011.60266210.3109\/10408444.2011.60266221838551","DOI":"10.3109\/10408444.2011.602662"},{"key":"2026051108202589498_j_acph-2020-0033_ref_006_w2aab3b7b3b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. G. Daugaard, U. Abildgaard, N. H. Holstein-Rathlou, I. Bruunshuus, D. Bucher and P. P. Leyssac, Renal tubular function in patients treated with high-dose cisplatin, Clin. Pharmacol. Ther.44 (1988) 164\u2013172; https:\/\/doi.org\/10.1038\/clpt.1988.13210.1038\/clpt.1988.1322840230","DOI":"10.1038\/clpt.1988.132"},{"key":"2026051108202589498_j_acph-2020-0033_ref_007_w2aab3b7b3b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. A. M. Abdelrahman, Y. Al Suleimani, A. Shalaby, M. Ashique, P. Manoj, A. Nemmar and B. H. Ali, Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice, Naunyn. Schmiedebergs Arch. Pharmacol. (2018); https:\/\/doi.org\/10.1007\/s00210-018-1564-710.1007\/s00210-018-1564-730206656","DOI":"10.1007\/s00210-018-1564-7"},{"key":"2026051108202589498_j_acph-2020-0033_ref_008_w2aab3b7b3b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. G. J. Dugbartey, L. J. Peppone and I. A. de Graaf, An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures, Toxicology371 (2016) 58\u201366; https:\/\/doi.org\/10.1016\/j.tox.2016.10.00110.1016\/j.tox.2016.10.001558659427717837","DOI":"10.1016\/j.tox.2016.10.001"},{"key":"2026051108202589498_j_acph-2020-0033_ref_009_w2aab3b7b3b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. C. N. Sharp and L. J. Siskind, Developing better mouse models to study cisplatin-induced kidney injury, Am. J. Physiol. Renal Physiol.313 (2017) F835-f841; https:\/\/doi.org\/10.1152\/ajprenal.00285.201710.1152\/ajprenal.00285.2017566858228724610","DOI":"10.1152\/ajprenal.00285.2017"},{"key":"2026051108202589498_j_acph-2020-0033_ref_010_w2aab3b7b3b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. M. Hurst and B. Jarvis, Perindopril: an updated review of its use in hypertension, Drugs61 (2001) 867\u2013896; https:\/\/doi.org\/10.2165\/00003495-200161060-0002010.2165\/00003495-200161060-0002011398915","DOI":"10.2165\/00003495-200161060-00020"},{"key":"2026051108202589498_j_acph-2020-0033_ref_011_w2aab3b7b3b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. P. A. Todd and A. Fitton, Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders, Drugs42 (1991) 90\u2013114; https:\/\/doi.org\/10.2165\/00003495-199142010-0000610.2165\/00003495-199142010-000061718688","DOI":"10.2165\/00003495-199142010-00006"},{"key":"2026051108202589498_j_acph-2020-0033_ref_012_w2aab3b7b3b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. E. M. de Cavanagh, F. Inserra and L. Ferder, Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?, Cardiovasc Res.89 (2011) 31\u201340; https:\/\/doi.org\/10.1093\/cvr\/cvq28510.1093\/cvr\/cvq28520819950","DOI":"10.1093\/cvr\/cvq285"},{"key":"2026051108202589498_j_acph-2020-0033_ref_013_w2aab3b7b3b1b6b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. E. A. M. El-Shoura, B. A. S. Messiha, S. M. Z. Sharkawi and R. A. M. Hemeida, Perindopril ameliorates lipopolysaccharide-induced brain injury through modulation of angiotensin-II\/angiotensin-1-7 and related signaling pathways, Eur. J. Pharmacol.834 (2018) 305\u2013317; https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.04610.1016\/j.ejphar.2018.07.04630059682","DOI":"10.1016\/j.ejphar.2018.07.046"},{"key":"2026051108202589498_j_acph-2020-0033_ref_014_w2aab3b7b3b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. N. E. Mohammed, B. A. Messiha and A. A. Abo-Saif, Effect of amlodipine, lisinopril and allopurinol on acetaminophen-induced hepatotoxicity in rats, Saudi Pharm. J.24 (2016) 635\u2013644; https:\/\/doi.org\/10.1016\/j.jsps.2015.04.00410.1016\/j.jsps.2015.04.004509442927829805","DOI":"10.1016\/j.jsps.2015.04.004"},{"key":"2026051108202589498_j_acph-2020-0033_ref_015_w2aab3b7b3b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. M. M. Abdel-Fattah, A. A. Salama, B. A. Shehata and I. E. Ismaiel, The potential effect of the angiotensin II receptor blocker telmisartan in regulating OVA-induced airway remodeling in experimental rats, Pharmacol. Rep.67 (2015) 943\u2013951; https:\/\/doi.org\/10.1016\/j.pharep.2015.02.01010.1016\/j.pharep.2015.02.01026398389","DOI":"10.1016\/j.pharep.2015.02.010"},{"key":"2026051108202589498_j_acph-2020-0033_ref_016_w2aab3b7b3b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. M. G. Fahmy Wahba, B. A. Shehata Messiha and A. A. Abo-Saif, Ramipril and haloperidol as promising approaches in managing rheumatoid arthritis in rats, Eur. J. Pharmacol.765 (2015) 307\u201315; https:\/\/doi.org\/10.1016\/j.ejphar.2015.08.02610.1016\/j.ejphar.2015.08.02626302059","DOI":"10.1016\/j.ejphar.2015.08.026"},{"key":"2026051108202589498_j_acph-2020-0033_ref_017_w2aab3b7b3b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. F. Barutta, S. Bellini, R. Mastrocola, R. Gambino, F. Piscitelli, V. di Marzo, B. Corbetta, V. K. Vemuri, A. Makriyannis, L. Annaratone, L. Annaratone, G. Bruno and G. Gruden, Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy, Br. J. Pharmacol.175 (2018) 4371\u20134385; https:\/\/doi.org\/10.1111\/bph.1449510.1111\/bph.14495624013030184259","DOI":"10.1111\/bph.14495"},{"key":"2026051108202589498_j_acph-2020-0033_ref_018_w2aab3b7b3b1b6b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. X. M. Gao, A. Tsai, A. Al-Sharea, Y. Su, S. Moore, L. P. Han, H. Kiriazis, A. M. Dart, A. J. Murphy and X. J. Du, Inhibition of the renin-angiotensin system post myocardial infarction prevents inflammation-associated acute cardiac rupture, Cardiovasc. Drugs Ther.31 (2017) 145\u2013156; https:\/\/doi.org\/10.1007\/s10557-017-6717-210.1007\/s10557-017-6717-228204966","DOI":"10.1007\/s10557-017-6717-2"},{"key":"2026051108202589498_j_acph-2020-0033_ref_019_w2aab3b7b3b1b6b1ab1ac19Aa","doi-asserted-by":"crossref","unstructured":"19. K. K. Filipski, R. H. Mathijssen, T. S. Mikkelsen, A. H. Schinkel and A. Sparreboom, Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity, Clin. Pharmacol. Ther.86 (2009) 396\u2013402; https:\/\/doi.org\/10.1038\/clpt.2009.13910.1038\/clpt.2009.139274686619625999","DOI":"10.1038\/clpt.2009.139"},{"key":"2026051108202589498_j_acph-2020-0033_ref_020_w2aab3b7b3b1b6b1ab1ac20Aa","doi-asserted-by":"crossref","unstructured":"20. F. A. Suliman, D. M. Khodeer, A. Ibrahiem, E. T. Mehanna, M. K. El-Kherbetawy, H. M. F. Mohammad, S. A. Zaitone and Y. M. Moustafa, Renoprotective effect of the isoflavonoid biochanin A against cisplatin induced acute kidney injury in mice: Effect on inflammatory burden and p53 apoptosis, Int. Immunopharmacol.61 (2018) 8\u201319; https:\/\/doi.org\/10.1016\/j.intimp.2018.05.01010.1016\/j.intimp.2018.05.01029793166","DOI":"10.1016\/j.intimp.2018.05.010"},{"key":"2026051108202589498_j_acph-2020-0033_ref_021_w2aab3b7b3b1b6b1ab1ac21Aa","doi-asserted-by":"crossref","unstructured":"21. A. S. Shalkami, M. I. A. Hassan and A. A. Abd El-Ghany, Perindopril regulates the inflammatory mediators, NF-kappaB\/TNF-alpha\/IL-6, and apoptosis in cisplatin-induced renal dysfunction, Naunyn. Schmiedebergs Arch. Pharmacol.391 (2018) 1247\u20131255; https:\/\/doi.org\/10.1007\/s00210-018-1550-010.1007\/s00210-018-1550-030066022","DOI":"10.1007\/s00210-018-1550-0"},{"key":"2026051108202589498_j_acph-2020-0033_ref_022_w2aab3b7b3b1b6b1ab1ac22Aa","doi-asserted-by":"crossref","unstructured":"22. I. Rubera, C. Duranton, N. Melis, M. Cougnon, B. Mograbi and M. Tauc, Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity, Cell Death Dis.4 (2013) e817; https:\/\/doi.org\/10.1038\/cddis.2013.35510.1038\/cddis.2013.355382466524091660","DOI":"10.1038\/cddis.2013.355"},{"key":"2026051108202589498_j_acph-2020-0033_ref_023_w2aab3b7b3b1b6b1ab1ac23Aa","doi-asserted-by":"crossref","unstructured":"23. H. Soni, D. Kaminski, R. Gangaraju and A. Adebiyi, Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding, Ren. Fail.40 (2018) 314\u2013322; https:\/\/doi.org\/10.1080\/0886022x.2018.145693810.1080\/0886022X.2018.1456938601430329619879","DOI":"10.1080\/0886022X.2018.1456938"},{"key":"2026051108202589498_j_acph-2020-0033_ref_024_w2aab3b7b3b1b6b1ab1ac24Aa","doi-asserted-by":"crossref","unstructured":"24. R. Goel, S. A. Bhat, K. Hanif, C. Nath and R. Shukla, Perindopril attenuates lipopolysaccharideinduced amyloidogenesis and memory impairment by suppression of oxidative stress and RAGE activation, ACS Chem. Neurosci.7 (2016) 206\u2013217; https:\/\/doi.org\/10.1021\/acschemneuro.5b0027410.1021\/acschemneuro.5b0027426689453","DOI":"10.1021\/acschemneuro.5b00274"},{"key":"2026051108202589498_j_acph-2020-0033_ref_025_w2aab3b7b3b1b6b1ab1ac25Aa","doi-asserted-by":"crossref","unstructured":"25. A. Dandekar, R. Mendez and K. Zhang, Cross talk between ER stress, oxidative stress, and inflammation in health and disease, Methods Mol. Biol.1292 (2015) 205\u201314; https:\/\/doi.org\/10.1007\/978-1-4939-2522-3_1510.1007\/978-1-4939-2522-3_1525804758","DOI":"10.1007\/978-1-4939-2522-3_15"},{"key":"2026051108202589498_j_acph-2020-0033_ref_026_w2aab3b7b3b1b6b1ab1ac26Aa","unstructured":"26. F. Sesti, O. E. Tsitsilonis, A. Kotsinas and I. P. Trougakos, Oxidative stress-mediated biomolecular damage and inflammation in tumorigenesis, In Vivo26 (2012) 395\u2013402."},{"key":"2026051108202589498_j_acph-2020-0033_ref_027_w2aab3b7b3b1b6b1ab1ac27Aa","doi-asserted-by":"crossref","unstructured":"27. K. Hasegawa, S. Wakino, K. Yoshioka, S. Tatematsu, Y. Hara, H. Minakuchi, N. Washida, H. Tokuyama, K. Hayashi and H. Itoh, Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression, Biochem. Biophys. Res. Commun.372 (2008) 51\u201356; https:\/\/doi.org\/10.1016\/j.bbrc.2008.04.17610.1016\/j.bbrc.2008.04.17618485895","DOI":"10.1016\/j.bbrc.2008.04.176"},{"key":"2026051108202589498_j_acph-2020-0033_ref_028_w2aab3b7b3b1b6b1ab1ac28Aa","doi-asserted-by":"crossref","unstructured":"28. M. H. Hassan, S. A. Bahashawan, T. M. Abdelghany, G. M. Abd-Allah and M. M. Ghobara, Crocin abrogates carbon tetrachloride-induced renal toxicity in rats via modulation of metabolizing enzymes and diminution of oxidative stress, apoptosis, and inflammatory cytokines, J. Biochem. Mol. Toxicol.29 (2015) 330\u2013339; https:\/\/doi.org\/10.1002\/jbt.2170210.1002\/jbt.2170225899501","DOI":"10.1002\/jbt.21702"},{"key":"2026051108202589498_j_acph-2020-0033_ref_029_w2aab3b7b3b1b6b1ab1ac29Aa","doi-asserted-by":"crossref","unstructured":"29. J. Y. Kim, J. H. Park, K. Kim, J. Jo, J. Leem and K. K. Park, Pharmacological inhibition of caspase-1 ameliorates cisplatin-induced nephrotoxicity through suppression of apoptosis, oxidative stress, and inflammation in mice, Mediators Inflamm.2018(2018) 6571676; https:\/\/doi.org\/10.1155\/2018\/657167610.1155\/2018\/6571676632343830670928","DOI":"10.1155\/2018\/6571676"},{"key":"2026051108202589498_j_acph-2020-0033_ref_030_w2aab3b7b3b1b6b1ab1ac30Aa","doi-asserted-by":"crossref","unstructured":"30. J. L. Martindale and N. J. Holbrook, Cellular response to oxidative stress: signaling for suicide and survival, J. Cell Physiol.192 (2002) 1\u201315; https:\/\/doi.org\/10.1002\/jcp.1011910.1002\/jcp.1011912115731","DOI":"10.1002\/jcp.10119"},{"key":"2026051108202589498_j_acph-2020-0033_ref_031_w2aab3b7b3b1b6b1ab1ac31Aa","doi-asserted-by":"crossref","unstructured":"31. G. Nunez, M. A. Benedict, Y. Hu and N. Inohara, Caspases: the proteases of the apoptotic pathway, Oncogene17 (1998) 3237\u20133245; https:\/\/doi.org\/10.1038\/sj.onc.120258110.1038\/sj.onc.12025819916986","DOI":"10.1038\/sj.onc.1202581"},{"key":"2026051108202589498_j_acph-2020-0033_ref_032_w2aab3b7b3b1b6b1ab1ac32Aa","doi-asserted-by":"crossref","unstructured":"32. E. A. Slee, M. T. Harte, R. M. Kluck, B. B. Wolf, C. A. Casiano, D. D. Newmeyer, H. G. Wang, J. C. Reed, D. W. Nicholson, E. S. Alnemri, D. R. Green and S. J. Martin, Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner, J. Cell Biol.144 (1999) 281\u2013292; https:\/\/doi.org\/10.1083\/jcb.144.2.28110.1083\/jcb.144.2.28121328959922454","DOI":"10.1083\/jcb.144.2.281"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/acph\/70\/4\/article-p515.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2020-0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:37:43Z","timestamp":1778488663000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2020-0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,5,13]]},"published-print":{"date-parts":[[2020,12,1]]}},"alternative-id":["10.2478\/acph-2020-0033"],"URL":"https:\/\/doi.org\/10.2478\/acph-2020-0033","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]}}}